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12y.o.), 55.4% were women. The average cost person/year was
euro 3502.87; 73.9% attributable to hospitalisations, 17.5% to
drugs, 8,6% to other medical costs. The 32.8% patients died
during the follow up period, with a mean age of 84 ± 9 statisti-
cally different (p < 0.0001) from survivors (mean age 74 ± 11
y.o.). CONCLUSIONS: Stroke imposes a large social and eco-
nomic burden on NHS and society because of the large number
of hospitalisation and the high rate of mortality. Future investi-
gations will be conduct to asses the relationships between comor-
bidity, costs, drug therapy and survival.
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OBJECTIVES: To assess factors inﬂuencing acute hospitalization
for patients with ﬁrst-ever ischemic stroke in Taiwan.
METHODS: Data were prospectively collected from 360 ﬁrst-
ever ischemic stroke patients consecutively admitted to a medical
center within 48 hours after symptom onset. Longer stay was
deﬁned as length of stay (LOS) >7 days after admission in depart-
ment of neurology for acute care. The association between demo-
graphic characteristics or clinical variables and LOS was
examined using multivariate logistic regression analysis. Dis-
crimination of the model was assessed by the area under the
receiver operating characteristic curve, and calibration was
assessed using goodness of ﬁt test. RESULTS: Patients (58%
male) had mean age 64.9 ± 12.7 (range, 18 to 93) years. Median
National Institutes of Health Stroke Scale (NIHSS) score at
admission was 6 (25th to 75th percentile, 3 to 12), median mod-
iﬁed Barthel Index (MBI; on a scale of 0 to 20) at admission was
12 (25th to 75th percentile, 5 to 16). The LOS was >7 days in
169 (47%) patients. Male sex (odds ratio [OR], 1.7; 95% CI,
1.0 to 2.8), baseline NIHSS score 7–15 (versus 0–6) (OR, 2.9;
95% CI, 1.5 to 5.7), baseline NIHSS score ≥16 (versus 0–6) (OR,
3.1; 95% CI, 1.3 to 7.4), baseline MBI ≥12 (OR, 0.5; 95% CI,
0.3 to 1.0), and small vessel occlusive subtype (OR, 0.35; 95%
CI, 0.2 to 0.6) were independent predictors of longer stay. Good-
ness-of-ﬁt test (Hosmer-Lemeshow test) was not signiﬁcant (P =
0.49), indicating adequate ﬁtness. The model’s discrimination
was adequate with an under the curve area (receiver operating
characteristic curve) of 0.776. CONCLUSIONS: The impact of
stroke severity need to be understood to manager LOS. Early
supported discharge planning would probably reduce the LOS
in acute hospitalization of this group of ﬁrst-ever ischemic stroke
patients.
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OBJECTIVES: Clinical practice guidelines and several clinical
trials support the use of warfarin for stroke prevention in most
patients with atrial ﬁbrillation (AF). Warfarin should not be used
in cases where contraindications exist or the risk of stroke is low.
It is not clear what proportion of are there patients at risk of
stroke and without contraindications do not receive warfarin in
practice. METHODS: A MEDLINE search was conducted
(1966–2001) using the MeSH terms anticoagulants, AF, warfarin
and cerebrovascular disorder (prevention and control). Practice-
based studies reporting the proportion of patients eligible to
receive warfarin (i.e., no contraindications to thromboprophy-
laxis and at moderate or high risk of stroke) who actually
received warfarin for stroke prevention in AF were retrieved.
RESULTS: Twenty-one practice-based studies were found, of
which 3 were excluded because the patient population or
centre/setting signiﬁcantly varied from the other identiﬁed
studies. Approximately 47–89% of patients enrolled in the
remaining 18 studies were eligible for stroke prevention. Only
15–64% of eligible patients received warfarin and 15–56% did
not receive any form of stroke prevention therapy at all (i.e., no
warfarin or antiplatelet agent). CONCLUSIONS: Despite the
publication of multiple clinical trials and practice guidelines sup-
porting the use of warfarin for stroke prevention in AF, many
eligible patients do not receive appropriate preventive therapy,
and therefore remain at increased risk of stroke. Reasons for the
sub-optimal use of warfarin for stroke prevention in AF require
further research.
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OBJECTIVES: There is a documented lack of treatment and
undertreatment with warfarin in AF patients. GPs and Special-
ists (SPs) may take different approaches to anticoagulation for
their AF patients. The objective is to identify, compare and 
quantify warfarin patient segments for both SPs and GPs.
METHODS: Physicians from Toronto, Montreal and Vancouver,
randomly recruited from lists of high warfarin prescribers, par-
ticipated in 60 minute qualitative interviews. Thirty-Six physi-
cians were interviewed (14GPs, 8 Cardiologists, 6 Internists and
3 Haematologists). RESULTS: SPs placed patients in 3 major 
segments: untreated (5% of their patients), treated (90–95%)
and undertreated (5%). GPs had only 2 segments: untreated
(10–25%) and treated (75–90%). Both physician groups identi-
ﬁed untreated patients as those at risk of falling, demented, prone
to bleed, immobile or refusing treatment. SPs referred to under-
treated patients as those using ASA. GPs saw ASA users as part
of their treated group. The other segment within the GP treated
group was warfarin users. SPs divided their treated segment into
well-controlled and not well-controlled. CONCLUSION: SPs
and GPs use similar criteria in determining which patients do not
receive warfarin. However, views on the value of ASA seem dif-
ferent. Further, GPs in this study did not distinguish between well
and not-well controlled warfarin, but rather indicated ASA vs.
warfarin users are both considered treated. Further research is
required to further investigate the differences in opinion, lack of
treatment and to quantify each segment.
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OBJECTIVES: To assess the properties of the Mandarin version
of the Stoke Impact Scale (SIS) versions 3.0, developed by Pamela
W. Duncan et al. METHODS: The SIS, a stroke-speciﬁc outcome
measure, assesses 8 domains: strength (4 items), memory (7
items), emotion (9 items), communication (7 items), activities of
daily living/instrumental activities of daily living (ADL/IADL)
(10 items), mobility (9 items), hand function (5 items), and par-
ticipation (8 items). SIS was translated and back-translated
